Skip to content
10-Q

Quarterly Report

Viridian Therapeutics, Inc.\DE VRDN

0001590750-26-000012

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 103.07M sh
Capex Q1 2026 · Mar 31, 2026 $23K
Capex Q1 2026 · Mar 31, 2025 $86K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$119.65M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$92.65M
Stockholders Equity Q1 2026 · Mar 31, 2026 $636.01M
Stockholders Equity Q1 2026 · Dec 31, 2025 $722.17M
Stockholders Equity Q1 2026 · Mar 31, 2025 $604.47M
Stockholders Equity Q1 2026 · Dec 31, 2024 $671.64M
Current Liabilities Q1 2026 · Mar 31, 2026 $51.81M
Current Liabilities Q1 2026 · Dec 31, 2025 $70.7M
Total Liabilities Q1 2026 · Mar 31, 2026 $153.01M
Total Liabilities Q1 2026 · Dec 31, 2025 $177.25M
Current Assets Q1 2026 · Mar 31, 2026 $784.74M
Current Assets Q1 2026 · Dec 31, 2025 $894.23M
Total Assets Q1 2026 · Mar 31, 2026 $789.02M
Total Assets Q1 2026 · Dec 31, 2025 $899.42M
Sga Expense Q1 2026 · Mar 31, 2026 $38.68M
Sga Expense Q1 2026 · Mar 31, 2025 $17.1M
Net Income Q1 2026 · Mar 31, 2026 −$104.9M
Net Income Q1 2026 · Mar 31, 2025 −$86.91M
Operating Income Q1 2026 · Mar 31, 2026 −$116.17M
Operating Income Q1 2026 · Mar 31, 2025 −$93.87M
Shares Diluted Q1 2026 · Mar 31, 2025 81.34M sh